IP Library Granted Patent US 7,186,543
Granted Patent B1
US 7,186,543 · App. 10/325,402 · Granted Mar 6, 2007

Preparation of vaccines using a photosensitizer and light

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,186,543
App. No.
10/325,402
Granted
Mar 6, 2007
Kind
B1
Abstract

Methods are provided for treating a vaccine containing infectious particles which may be viral, bacterial, and/or cellular in nature. Preferred methods include the steps of adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid and exposing the fluid to photoradiation sufficient to inactivate the infectious particles but not enough to damage the antigenic characteristics of the infectious particles.

Claims (17)

1. A method of making a vaccine from one or more infectious particles comprising:

inactivating the infectious particles by adding an effective amount of an endogengous isoalloxazine photosensitizer to the one or more infectious particles and exposing the particles to light of a sufficient wavelength to prevent replication of the infectious particles but not substantially destroy the antigenic determinants of the particles; and

suspending the inactivated particles in a suspension solution to create a vaccine.

2. The method of claim 1 wherein the infectious particles are viruses.

3. The method of claim 1 wherein the particles are rendered non-infectious by preventing the replication of the infectious particles.

4. A method of making a vaccine containing a live virus comprising the steps of:

adding an effective amount of an endogenous isoalloxazine photosensitizer to the virus and exposing the virus to light of a sufficient wavelength to prevent replication of the live virus but not substantially destroy the antigenic determinants of the virus to create an inactivated live virus; and

suspending the inactivated live virus in a suspension solution to create a vaccine.

5. The method of claim 4 wherein the suspension solution is chosen from the group consisting of: saline and water.

6. The method of claim 4 wherein the suspension solution comprises an antibiotic and a preservative.

7. The method of claim 4 wherein the suspension solution comprises an adjuvant.

8. A method for inactivating infectious particles without substantially degrading the antigenic characteristics of the particles, comprising the steps of:

exposing the infectious particles to an inactivation fluid containing at least an endogenous isoalloxazine photosensitizer in an amount sufficient to render the particles substantially non-infectious; and

exposing the infectious particles and inactivation fluid to light of a sufficient wavelength and for a sufficient time to render the particles substantially non-infectious but less than that which would result in degradation of the antigenic characteristics of the infectious particles.

9. The step of claim 8 wherein the particles are rendered non-infectious by preventing the replication of the infectious particles.

10. The method of claim 8 wherein the infectious particles are viruses.

11. The method of claim 8 wherein an enhancer is added to the inactivation fluid before the step of exposing the infectious particles and inactivation fluid to light.

Assignments (2)
CHANGE OF NAME Recorded Feb 16, 2012
From: CARIDIANBCT BIOTECHNOLOGIES, LLC.
To: TERUMO BCT BIOTECHNOLOGIES, LLC
Reel/Frame 027715/0552 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2011
From: CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT
To: CARIDIANBCT BIOTECHNOLOGIES, LLC
Reel/Frame 026192/0547 →